Capital Management Corp VA Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)

Capital Management Corp VA lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 15.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 238,379 shares of the biopharmaceutical company’s stock after acquiring an additional 31,103 shares during the quarter. Bristol-Myers Squibb accounts for about 2.2% of Capital Management Corp VA’s holdings, making the stock its 18th biggest position. Capital Management Corp VA’s holdings in Bristol-Myers Squibb were worth $12,334,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Reston Wealth Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $25,000. ESL Trust Services LLC purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $27,000. Valued Wealth Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 1,168.1% during the 3rd quarter. Valued Wealth Advisors LLC now owns 596 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 549 shares in the last quarter. ORG Wealth Partners LLC purchased a new stake in Bristol-Myers Squibb in the 3rd quarter valued at approximately $34,000. Finally, LGT Financial Advisors LLC lifted its stake in Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 227 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 2.1 %

BMY stock opened at $55.45 on Tuesday. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The business has a fifty day simple moving average of $51.41 and a 200-day simple moving average of $46.61. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $56.20.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. During the same period in the prior year, the company earned $2.00 EPS. The firm’s revenue was up 8.4% on a year-over-year basis. As a group, analysts predict that Bristol-Myers Squibb will post 0.83 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.33%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -66.85%.

Analyst Ratings Changes

A number of research firms recently issued reports on BMY. Barclays upped their target price on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. Deutsche Bank Aktiengesellschaft reduced their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $50.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. Finally, TD Cowen upped their target price on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $53.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.